Medibank (ASX:MPL) recently held its Annual General Meeting (AGM), where it reaffirmed key guidance metrics for the fiscal year 2024. Additionally, the Australian Prudential Regulation Authority (APRA) has released industry statistics for the Private Health Insurance (PHI) sector for the September quarter. In this analysis, we'll delve into these updates and provide insights into their implications for Medibank and the broader industry.

Medibank AGM Highlights

At the AGM, Medibank reiterated its guidance metrics for the fiscal year 2024, signalling confidence in its performance and outlook. This reaffirmation provides stakeholders with clarity and reassurance regarding the company's trajectory.

APRA's PHI Industry Statistics

APRA's release of industry statistics for the PHI sector offers valuable insights into market dynamics. Notably, the statistics indicate continued reasonable growth in industry policyholders, albeit with rising hospital treatment benefit growth, suggesting evolving trends within the sector.

Forecast Adjustments

Following a review of our earnings assumptions, we have made nominal changes to our Medibank EPS forecasts, reflecting adjustments of approximately 2%. Despite these adjustments, our price target remains largely unchanged.

Analysis

While the current operating environment appears relatively favourable for Medibank, with continued growth in policyholders and reasonable industry dynamics, we maintain a cautious stance. Trading at 18x FY24F PE, we view Medibank as fair value. Therefore, we maintain our HOLD recommendation on the stock.

In conclusion, the updates from Medibank's AGM and APRA's industry statistics offer valuable insights into the company's performance and broader market trends. As always, investors should conduct thorough research and consider their investment goals before making any decisions.

<<Insert button>>

Disclaimer: The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.

News & Insights

This edition of the Month Ahead presents ideas from three areas of focus for Morgans: domestic equities, ETFs and global equities. We take a look at the opportunities presented by Light & Wonder, the Firetrail Australian Small Companies Fund and Eli Lilly.
Read full article
We recommend investors start making sense of AI by considering stock opportunities in three distinct areas: artificial intelligence, digital infrastructure, and data networks.
Read full article
Most results were thereabouts against expectations which saw the sector perform broadly in line with the index. Top picks are ALQ and CVL.
Read full article

News & Insights

Medibank (ASX:MPL) had hosted its AGM, with the company re-affirming key FY24 guidance metrics.
Find out more